La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Viveve Medical Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	6.7yrs
Durata media del Consiglio di amministrazione	6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Viveve to get US patent for technology to treat female stress urinary incontinence

Oct 04

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Dec 03

AMMINISTRATORE DELEGATO

Viveve Medical non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jim Robbins	Senior VP of Finance & Administration and Principal Accounting & Financial Officer	7.2yrs	US$701.05k	Nessun dato
Deborah Jorn	Senior Advisor to the CEO & Director	6.3yrs	US$208.88k	Nessun dato
Martin Kerber	Vice President of Research	6.7yrs	Nessun dato	Nessun dato
Jeannie Swindle	Senior Director of Corporate Communications	no data	Nessun dato	Nessun dato
Jeff Sinclair	Vice President of International Sales	no data	Nessun dato	Nessun dato
Gary Kaiser	Vice President of Global Marketing	no data	Nessun dato	Nessun dato
Lori McMillan	Vice President of Human Resources	7.3yrs	Nessun dato	Nessun dato
Suzon Lommel	Senior Vice President of Regulatory & Quality Affairs	6.7yrs	Nessun dato	Nessun dato

6.7yrs

Durata media

66yo

Età media

Gestione esperta: Il team dirigenziale di VIVE è esperto e expertise (durata media dell'incarico 6.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Deborah Jorn	Senior Advisor to the CEO & Director	8.3yrs	US$208.88k	Nessun dato
Steven Basta	Independent Chairman of the Board	6yrs	US$469.44k	Nessun dato
Alan Wein	Member of Clinical Advisory Board in Urinary Incontinence	no data	Nessun dato	Nessun dato
Sharon Presnell	Independent Director	3.9yrs	US$196.13k	Nessun dato
Roger Dmochowski	Member of Clinical Advisory Board in Urinary Incontinence	no data	Nessun dato	Nessun dato
Mickey Karram	Member of Clinical Advisory Board in Urinary Incontinence	no data	Nessun dato	Nessun dato
Kathleen Kobashi	Member of Clinical Advisory Board in Urinary Incontinence	no data	Nessun dato	Nessun dato
Scott MacDiarmid	Member of Clinical Advisory Board in Urinary Incontinence	no data	Nessun dato	Nessun dato
Eric Rovner	Member of Clinical Advisory Board in Urinary Incontinence	no data	Nessun dato	Nessun dato

6.0yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VIVE sono considerati esperti (durata media dell'incarico 5.9 anni).

Viveve Medical Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Viveve Medical, Inc. Appoints Sharon Collins Presnell to the Board of Directors and Its Audit Committee, Effective October 28, 2020

Recent updates

InMode Ltd. (NasdaqGS:INMD) acquired Intellectual Property Assets of Viveve Medical Inc.

Viveve Medical, Inc.(OTCPK:VIVE) dropped from NASDAQ Composite Index

Viveve Medical, Inc. Intends to File A Form 15 with the Securities and Exchange Commission

Viveve Medical, Inc. Announces Completion of Pivotal US Pursuit Trial for Female Stress Urinary Incontinence

Viveve Medical Receives Notice from the Listing Qualifications Staff of Nasdaq

Viveve Medical Receives a Non-Compliance Letter from Nasdaq

Price target decreased to US$4.68

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viveve Medical, Inc. announced that it has received $0.014675 million in funding

Viveve Medical, Inc. Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Viveve to get US patent for technology to treat female stress urinary incontinence

Viveve Medical, Inc. Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal Pursuit Trial Readout

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viveve Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Viveve Medical receives patent for dual-energy technology in Taiwan

Viveve Medical Receives a Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to US$6.88

Consensus revenue estimates fall by 15%

Price target decreased to US$9.63

Viveve Medical, Inc. Announces Initiation of Pivotal U.S. Pursuit Trial in Stress Urinary Incontinence

Viveve Medical, Inc. has completed a Composite Units Offering in the amount of $23.999988 million.

Viveve under pressure after upsizes capital raise, prices offering at $3.40

Viveve Regains Compliance with Nasdaq Continued Listing Rules

Viveve regains compliance with Nasdaq

Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Viveve Medical, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Viveve Medical, Inc. Appoints Sharon Collins Presnell to the Board of Directors and Its Audit Committee, Effective October 28, 2020

Viveve Medical, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Viveve Medical, Inc. announced that it expects to receive $10 million in funding from Lincoln Park Capital, LLC

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media